Mexican Pharma Sector Continues In Crisis

11 August 1996

Although the administration of Mexico's President Ernesto Zedillo Ponce de Leon has consistently affirmed that the country's economic crisis (sparked by the peso devaluation in December 1994) is no longer a problem, his optimism is belied by the grave problems still existing.

In the pharmaceutical sector, a total of 3,000 firms, including pharmacies, smaller laboratories and allied sector companies have gone into bankruptcy and/or have closed their operations, and the outlook for 8,000 more firms looks grim, the Marketletter's local correspondent says.

In view of the gravity of the situation, the Ministry of Commerce has said it will initiate a "rescue operation" for the sector, including aid for ailing small and medium-sized operations, which includes low interest loans by the National Domestic Trade Bank. Meantime, the elimination of unfair pricing policies of some laboratories was called for by pharmacists.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight